1. Bakris G, Fonseca V, Sharma K, Wright E. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009; 75:1272–1277.
Article
2. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010; 95:34–42.
Article
3. Kim WJ, Kim SS. The side effects of sodium glucose cotransporter 2 (SGLT2) inhibitor. J Korean Diabetes. 2014; 15:158–162.
Article
4. FDA safety alert. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 15 May 2015.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364–1379.
Article
6. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Management of hyperglycemic crisis in patients with diabetes. Diabetes Care. 2001; 24:131–153.
7. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006; 29:2739–2748.
Article
8. Ennis ED, Stahl EJVB, Kreisberg RA. The hyperosmolar hyperglycemic syndrome. Diabetes Rev. 1994; 2:115–126.
9. Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am. 2000; 29:683–705.
Article
10. Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto , et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014; 4:e125.
Article
11. Hamamoto H, Noda M. Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report. Am J Case Rep. 2015; 16:863–867.
Article
12. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38:1730–1735.
Article